Tonix Pharmaceuticals Holding Corp. (TNXP)
| Market Cap | 172.66M +126.4% |
| Revenue (ttm) | 13.11M +29.8% |
| Net Income | -124.02M |
| EPS | -14.57 |
| Shares Out | 13.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 766,750 |
| Open | 13.57 |
| Previous Close | 13.75 |
| Day's Range | 12.70 - 13.65 |
| 52-Week Range | 12.70 - 69.97 |
| Beta | 1.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 12, 2026 |
About TNXP
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingu... [Read more]
Financial Performance
In 2025, TNXP's revenue was $13.11 million, an increase of 29.85% compared to the previous year's $10.09 million. Losses were -$124.02 million, -4.63% less than in 2024.
Financial StatementsNews
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and trigem...
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announce...
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today an...
Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum
Tonix Pharmaceuticals reported Q4 GAAP EPS of -$3.98 (miss), but revenue surged 109% YoY to $5.39M, beating consensus by $2.42M. Early Tonmya launch metrics show promising initial uptake, with 4,200 p...
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares are up during Friday's premarket session as the company recently reported its fourth-quarter and full-year financial results, highlighting sig...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA t...
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia
Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 ...
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain re...
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain re...
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in ad...
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting
CHATHAM, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today t...
Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting
Tonix Pharmaceuticals Inc. (NASDAQ: TNXP) shares are down during Tuesday's premarket session following the company's recent uplisting to the Nasdaq Global Select Market.
Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market
BERKELEY HEIGHTS, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today an...
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March
BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today ann...
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabo...
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
BERKELEY HEIGHTS, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced tod...
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
CHATHAM, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial stage biotechnology company, today announc...
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry Ms. Ishak brings more than 25 years of corporate legal and strategic leadership...
Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications
Tonix Pharmaceuticals Holding Corp. received FDA approval and launched Tonmya, the first new fibromyalgia drug in over 15 years. TNXP is expanding Tonmya into acute stress disorder [ASD] and major dep...
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
TONMYA is now available by prescription and available for pharmacy ordering nationwide TONMYA is the first FDA-approved treatment for fibromyalgia in more than 15 years TONMYA is a unique, non-opioid,...
Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook
Tonix Pharmaceuticals is preparing for the commercial launch of Tonmya, a new FDA-approved fibromyalgia therapy, in November 2025. 3Q25 results showed revenue growth and a strong cash position, but hi...